Statements (88)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antipsychotic medication |
| gptkbp:approvalYear |
1996
|
| gptkbp:approvedBy |
gptkb:United_States
gptkb:FDA |
| gptkbp:ATCCode |
gptkb:N05AH03
|
| gptkbp:bioavailability |
60%
|
| gptkbp:brand |
gptkb:Zydis
gptkb:Zyprexa Relprevv |
| gptkbp:CASNumber |
gptkb:132539-06-1
|
| gptkbp:category |
antipsychotics
Eli Lilly and Company brands serotonin-dopamine antagonists |
| gptkbp:chemicalClass |
thienobenzodiazepine
|
| gptkbp:contraindication |
hypersensitivity to olanzapine
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:drugInteraction |
gptkb:beer
gptkb:fluvoxamine gptkb:levodopa gptkb:CNS_depressants gptkb:carbamazepine ciprofloxacin antihypertensives |
| gptkbp:eliminationHalfLife |
21 to 54 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:form |
gptkb:tablet
intramuscular injection orally disintegrating tablet |
| gptkbp:hasMolecularFormula |
gptkb:C17H20N4S
|
| https://www.w3.org/2000/01/rdf-schema#label |
olanzapine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
antagonist of histamine H1 receptors
antagonist of adrenergic alpha-1 receptors antagonist of dopamine D2 receptors antagonist of muscarinic receptors antagonist of serotonin 5-HT2A receptors |
| gptkbp:metabolism |
liver
|
| gptkbp:notRecommendedFor |
dementia-related psychosis
|
| gptkbp:overdoseSymptoms |
gptkb:arrhythmia
delirium coma seizures respiratory depression tachycardia agitation |
| gptkbp:patentExpired |
2011 (US)
|
| gptkbp:pregnancyCategory |
gptkb:C_(UK)
C (US) B3 (Australia) |
| gptkbp:prescribes |
adults
adolescents (in some countries) |
| gptkbp:prescriptionStatus |
Rx-only
|
| gptkbp:proteinBinding |
93%
|
| gptkbp:riskFactor |
gptkb:diabetes_mellitus
gptkb:metabolic_syndrome seizures QT prolongation hyperlipidemia stroke (elderly with dementia) |
| gptkbp:routeOfAdministration |
oral
intramuscular injection |
| gptkbp:sideEffect |
gptkb:orthostatic_hypotension
constipation weight gain elevated liver enzymes drowsiness sedation dry mouth extrapyramidal symptoms neuroleptic malignant syndrome tardive dyskinesia dyslipidemia increased appetite hyperglycemia akathisia increased prolactin |
| gptkbp:usedFor |
bipolar disorder
schizophrenia treatment-resistant depression bipolar depression acute mania |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:CYP1A2*1F
gptkb:cytochrome_P450_1A2 gptkb:Zyprexa |
| gptkbp:bfsLayer |
6
|